Peep into anti-vascular endothelial growth factor
Authors:
Open Access
- 29 April 2026
- journal article
- review article
- Published by Wolters Kluwer Health in Indian Journal Of Ophthalmology
- Vol. 74 (5) , 635-638
Abstract
Anti-vascular endothelial growth factor (anti-VEGF) therapy has transformed the management of retinal vascular diseases over the past two decades. Beginning with the foundational identification of VEGF as the principal driver of ocular neovascularization, the field has evolved from early agents such as pegaptanib and bevacizumab to more potent molecules including ranibizumab, aflibercept, brolucizumab, and faricimab. In India, the landscape is shaped by unique economic and epidemiological factors, including a high burden of diabetic retinopathy and age-related macular degeneration, limited healthcare reimbursement, and the significant role of biosimilar ranibizumab products in expanding access. This article provides a comprehensive overview of the historical development, pharmacology, regulatory milestones, safety considerations, and current clinical use of anti-VEGF agents in the Indian context, with emphasis on strategies to deliver equitable, high quality retinal care across a diverse population.Keywords
This publication has 40 references indexed in Scilit:
- Intravitreal aflibercept 8 mg in neovascular age-related macular degeneration (PULSAR): 48-week results from a randomised, double-masked, non-inferiority, phase 3 trialThe Lancet, 2024
- Intravitreal anti-vascular endothelial growth factor and combined photodynamic therapy for pachychoroid neovasculopathy: long-term treatment outcomesGraefe's Archive for Clinical and Experimental Ophthalmology, 2024
- Clinical Characteristics and Outcomes of Eyes with Intraocular Inflammation after Brolucizumab: Post Hoc Analysis of HAWK and HARRIEROphthalmology Retina, 2022
- Efficacy, durability, and safety of intravitreal faricimab up to every 16 weeks for neovascular age-related macular degeneration (TENAYA and LUCERNE): two randomised, double-masked, phase 3, non-inferiority trialsThe Lancet, 2022
- HAWK and HARRIER: Phase 3, Multicenter, Randomized, Double-Masked Trials of Brolucizumab for Neovascular Age-Related Macular DegenerationOphthalmology, 2020
- Aflibercept, Bevacizumab, or Ranibizumab for Diabetic Macular EdemaOphthalmology, 2016
- Ranibizumab in Myopic Choroidal Neovascularization: The 12-Month Results from the REPAIR StudyOphthalmology, 2013
- Intravitreal Aflibercept (VEGF Trap-Eye) in Wet Age-related Macular DegenerationOphthalmology, 2012
- Ranibizumab for Macular Edema following Central Retinal Vein OcclusionOphthalmology, 2010
- Pegaptanib Sodium for Neovascular Age-Related Macular DegenerationOphthalmology, 2006